On July 31, 2022, Shengbai Oral Liquid (mixture) marrow suppression Summit Forum was successfully held in Nanjing, Jiangsu Province, the ancient capital of Jinling, which enjoys the title of "world literary hub". This meeting took the form of offline as the home field and online teachers joined. An academic forum was held to discuss the pathogenesis of myelosuppression, a common adverse reaction in the overall diagnosis and treatment of tumor, and the mechanism, clinical application and effectiveness of Shengbai oral liquid (mixture) in the treatment of myelosuppression.

The meeting was chaired by Prof. Shu Yongqian from Jiangsu Provincial People's Hospital, Prof. Wang Keming from the Second Affiliated Hospital of Nanjing Medical University, Prof. Jiang Hua from Changzhou Second People's Hospital, Prof. Fan Lei, Prof. Wang Tongshan, Prof. Sun Jing, Associate Professor Wu Hao, Associate Professor Qin Azine, Deputy Director He Liang, etc., Prof. Cui Xiaonan, the First Affiliated Hospital of Dalian Medical University; Vice Director Pu Xiaolin, Vice Director Zhu Wenyu, Vice Director Hang Junjie, the Second People's Hospital of Changzhou; Vice Director Ji Wenjing, Vice Director Xiao Min, the Fourth People's Hospital of Changzhou; Zhao Gang, deputy director of Changzhou Wujin People's Hospital, and many other experts and discussion guests had an in-depth discussion on "The mechanism and application of Shengbai Oral Liquid (mixture) on bone marrow suppression". The meeting was a combination of offline and online, and experts gathered together in a strong academic atmosphere, which was praised both online and offline.

During the meeting, Professor Shu Yongqian acknowledged the overall clinical performance of Shengbai Oral liquid (mixture). At the same time, Professor Wang Keming and Professor Jiang Hua, who presided over the first half of the mechanism, and Professor Wang Keming, who presided over the second half of the case application.

In the first half of the mechanism chapter, Professor Cui Xiaonan from the First Affiliated Hospital of Dalian Medical University made a special interpretation on the pathogenesis of bone marrow suppression and the limitations of the application of rising white needle in the process of tumor treatment, and explained that the treatment of bone marrow suppression by integrated traditional and western medicine plays a very important role in the overall treatment of disease. The mechanism of Shengbai Oral liquid (mixture) is in line with the needs of comprehensive diagnosis and treatment of bone marrow suppression. Then, Pu Xiaolin, deputy director of the Second People's Hospital of Changzhou City, made an in-depth interpretation of the mechanism of action of Shengbai oral liquid (mixture). Both from the source and from the index, it has an obvious effect on the promotion of white blood cells, and the evidence-based evidence is sufficient, and the expert recommendation is relatively complete. Panelists also made excellent discussions on the topic. Finally, the host Professor Jiang Hua also made a summary of the academic topics in the first half, highlighting the good performance of Birth white oral liquid (mixture) for preventive application, bone marrow reserve and immune regulation.

The second half of the application of cases followed, sharing and comment on the two cases of patients with leukopenia caused by chemotherapy and radiotherapy using Shengbai oral liquid, preventive application of Shengbai oral liquid, can effectively reduce the degree of leukopenia, and the longer the administration time, the more continuous improvement of efficacy, can ensure the smooth completion of radical chemoradiotherapy, improve patient compliance. Shengbai Oral liquid has remarkable curative effect among oral drugs, which is of great significance for the protection of radical radiotherapy combined with chemotherapy. In the following guest discussion session, experts expressed their views on how to better apply Shengbai oral liquid (mixture) in clinical practice and what aspects can be further studied. The overall atmosphere was very warm. At the end of the second half, Professor Wang Keming also made a summary of the meeting. The academic height of the conference and the overall level of the cases were highly evaluated.

At the end of the conference, Professor Shu Yongqian made a summary of the whole conference, highlighting that Shengbai oral liquid (mixture) has a remarkable therapeutic effect on mild leukopenia, which can warm and replenish the body, and has a profound significance in the prevention of severe leukopenia, which can reduce the application of injections, and at the same time encourage us to continue to increase academic investment and keep innovating. To find more rules of combining Shengbai oral liquid (mixture) with chemotherapy drugs, and further expand the clinical influence.

This conference has achieved a complete success, showing the effectiveness and superior effectiveness of Shengbai oral liquid (mixture) in the process of clinical application, providing the participating experts with better experience in clinical application of Shengbai oral liquid (mixture), and also pointing out certain direction of how to better apply Shengbai oral liquid (mixture) in clinical application. Mengyang Pharmaceutical will continue to work hard and innovate. In order to improve the standardized level of Chinese integrated traditional and western medicine treatment of malignant tumors, reduce the incidence of toxic and side effects of tumor treatment, improve the quality of life of patients, and ensure medical safety continue to make their own contribution!